BRIEF published on 04/03/2025 at 13:24, 11 months 15 days ago Innate Pharma participates in the Stifel 2025 Virtual Targeted Oncology Forum Euronext Paris Oncology Immunotherapy Innate Pharma Virtual Forum
BRIEF published on 04/03/2025 at 13:18, 11 months 15 days ago Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum Biotechnology Immunotherapy Virtual Event Innate Pharma Oncology Forum 2025
PRESS RELEASE published on 04/03/2025 at 13:13, 11 months 15 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Innate Pharma to participate in 2025 Stifel Virtual Targeted Oncology Forum. Executive team presenting and hosting 1x1 meetings. Focus on innovative cancer immunotherapies Cancer Innate Pharma Immunothérapies Stifel Targeted Oncology Forum
PRESS RELEASE published on 03/28/2025 at 14:37, 11 months 21 days ago Annual financial and audit reports / Annual financial report
BRIEF published on 03/20/2025 at 07:05, 11 months 29 days ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 11 months 29 days ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 1 month ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 1 month ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 1 month ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 1 month ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
Published on 03/18/2026 at 21:00, 2 hours 24 minutes ago PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 4 hours 19 minutes ago Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 5 hours 14 minutes ago Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures
Published on 03/18/2026 at 14:30, 8 hours 54 minutes ago Ground Geophysics Underway at Murphy Lake, 5 km From Isoenergy's Hurricane Deposit, Athabasca Basin
Published on 03/18/2026 at 14:15, 9 hours 9 minutes ago Apex Provides Phase I Drilling Update at the Rift Rare Earth Project in Nebraska, U.S.A.
Published on 03/18/2026 at 22:00, 1 hour 24 minutes ago aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
Published on 03/18/2026 at 18:53, 4 hours 30 minutes ago EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 4 hours 47 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:15, 5 hours 8 minutes ago Northern Data Group releases audited FY 2025 Financial Results
Published on 03/18/2026 at 19:41, 3 hours 42 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 5 hours 24 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 5 hours 39 minutes ago Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
